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The global population aging is accelerating and age-associated diseases including cardio-
vascular diseases become more challenging. The underlying mechanisms of aging and
age-associated cardiovascular dysfunction remain elusive.There are substantial evidences
demonstrating a pivotal role of the mammalian target of rapamycin complex 1 (mTORC1)
and its down-stream effector S6K1 signaling in mammalian lifespan regulation and age-
related diseases such as type II diabetes mellitus and cancer.The role of mTORC1–S6K1 in
age-related cardiovascular diseases is, however, largely unknown and the available experi-
mental results are controversial.This review article primarily summarizes the most recent
advances toward understanding the role of mTORC1–S6K1 in cardiovascular aging and dis-
cusses the future perspectives of targeting mTORC1–S6K1 signaling as a healthy lifespan
extension modality in anti-aging and anti-cardiovascular aging.
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INTRODUCTION
Global population aging is accelerating,which has been predicted
to be a great challenge for our society in the twenty-ﬁrst century
(Christensen et al., 2009). This is due to the steady achievements
of medicine and public healthcare over the past century, having
resultedinanincreasedlifeexpectancy,whichismainlyattributed
toimprovementof infantandchildhoodsurvivalandreductionof
mortality in the elderly population (Christensen et al.,2008,2009;
Rau et al., 2008). It has been predicted that the global propor-
tion above age 60 will increase from 10% of the total population
in 2000 to 21.8% in 2050 and 32.2% in 2100 (Lutz et al., 2008).
With the increased aging population, we are confronted with an
increase in age-associated diseases including cardiovascular dis-
ease,cancer,diabetes,andneurodegenerativedisease(Christensen
et al., 2009). Although aging has been proven to be an prominent
independent risk factor for cardiovascular disease (Najjar et al.,
2005),themechanismsof agingandage-associatedcardiovascular
dysfunction are still elusive. There are substantial evidences sug-
gesting that oxidative stress plays a crucial role in cardiovascular
aging (Ungvari et al., 2010). However, several prospective clinical
trials with various combinations of antioxidants fail to show sig-
niﬁcant effects on the incidence of major adverse cardiovascular
events (Vivekananthan et al., 2003; Sesso et al., 2008). The results
suggest that more thorough research on the mechanisms of aging
and age-associated cardiovascular diseases is required.
Researchinthepastyearsprovidescompellingevidencesshow-
ing a potential role of the target of rapamycin (TOR) signaling
pathway in lifespan regulation, which is remarkably conserved
across various species. In model systems such as yeast, nema-
todes, fruit ﬂies, and also recently in mice, inhibition of TOR
signaling increases lifespan (Evans et al., 2011). A role of dereg-
ulated mammalian TOR (mTOR) signaling in mammalian aging
andage-relateddiseasessuchastypeIIdiabetesmellitusandcancer
aredemonstrated(Evansetal.,2011).TheroleofmTOR,especially
its down-stream effector S6K1 in age-related cardiovascular dis-
eases or cardiovascular aging is, however, largely unknown. The
primary emphasis of this review article is to discuss emerging
evidence and future perspectives for a role of mTOR and S6K1
signaling in mammalian aging and age-associated cardiovascular
diseases.
BRIEF BIOCHEMISTRY OF mTOR SIGNALING
mTOR is a serine/threonine protein kinase which serves as intra-
cellular sensor for energy, nutrients, and stress, regulating cellular
and organism growth and metabolism. Therefore, dysfunctional
mTOR signaling has been considered a central integral mecha-
nism linking aging,metabolic disorders,and cancer (Zoncu et al.,
2011). The detailed molecular signaling network and regulation
of mTOR signaling have been reviewed comprehensively in sev-
eral articles (Dann et al., 2007; Sengupta et al., 2010; Evans et al.,
2011; Zoncu et al., 2011). A few important biochemical fea-
tures of mTOR signaling network are summarized in Figure 1.
mTOR,with other molecular components,forms two structurally
and functionally distinct complexes namely mTOR complex 1
(mTORC1) and mTOR complex 2 (mTORC2). In these com-
plexes,mTOR functions as the catalytic subunit and its enzymatic
activityisregulatedanddistinguishedbyitsuniqueaccessorypro-
teinsRaptorandRictor,respectively.RaptorandRictorfunctionas
scaffold proteins for assembling mTORC1 and mTORC2 and also
for binding substrates and regulators in the respective complex.
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FIGURE 1 | Major distinct characteristics of the two known mTOR
signaling complexes, mTORC1 and mTORC2, in composition,
rapamycin sensitivity, upstream signals, substrates, and biological
functions. Adapted from Foster and Finger (2010) and from Zoncu et al.
(2011). 4E-BP1, eIF4E-binding protein 1; AMPK, AMP kinase; Atg,
autophagy-related; FIP200, 200kDa FAK family kinase-interacting protein;
FOXO, forkhead box protein O; PPARγ, peroxisome proliferator-activated
receptor-γ; REDD1, regulated in development and DNA damage response
1; Rom2, Rho1 GDP–GTP exchange protein-2; SGK, serum- and
glucocorticoid-regulated kinase; SREBP , sterol regulatory element-binding
protein;TSC, the tuberous sclerosis.
In addition to their different protein compositions, there are a
few major important biochemical characteristics which distin-
guishthetwocomplexes:(1)sensitivitytotheimmunosuppressant
rapamycin: rapamycin inhibits mTORC1 but not mTORC2 activ-
ity,althoughprolongedtreatmentwithrapamycinhasbeenshown
to be capable of inhibiting mTORC2 in certain cell types (Sar-
bassov et al., 2006); (2) the upstream signals they integrate: while
mTORC2 seems to be regulated only by growth factors,mTORC1
is regulated by many stimuli including growth factors,energy sta-
tus, stressors such as DNA damage, hypoxia, and nutrients. The
small GTPase protein Rheb has been identiﬁed to be the key end
point for mTORC1 activation by stimulating kinase activity of
mTORC1. The TSC1–TSC2, a GTPase activating protein (GAP),
negatively modulates Rheb by converting the active form Rheb-
GTP into its inactive form Rheb-GDP through its GAP activity
and thus reduces mTORC1 activity. Except nutrient amino acids,
allof theabovementionedstimuliinputsregulatemTORC1activ-
ity through modulation of TSC1–TSC2 activity. Growth factors
inactivate TSC1–TSC2 via Akt/ERK1/2, leading to formation of
Rheb-GTP and ultimately mTORC1 activation, whereas energy
deﬁcit, DNA damage, or hypoxia activate TSC1–TSC2 through
activation of AMPK or REDD1 (regulated in development and
DNA damage response 1), respectively, resulting in inactivation
of Rheb and thus inhibition of mTORC1. Amino acids activate
mTORC1 independently of TSC1–TSC2, but through action of
Rag GTPases. In the presence of amino acids, Rag GTPases inter-
act with mTORC1 and translocate the complex from cytoplasm
to lysosomal membranes where it is activated by Rheb. For more
detaileddiscussionabouttheregulatorymechanismsof mTORC1
activation by various inputs, please refer to the review article by
Zoncuetal.(2011).IncontrasttomTORC1,theregulatorymech-
anisms and functions of mTORC2 signaling are less well charac-
terized;(3)thesubstratetheyregulateandthebiologicalprocesses
they control: mTORC1 enhances protein synthesis through S6K1
and eIF4E-binding protein 1 (4E-BP1). Upon phosphorylation
by mTORC1, 4E-BP1 dissociates from eIF4E, relieving its sup-
pressing effect on mRNA translation,while S6K1,when phospho-
rylated by mTORC1, promotes mRNA translation. In addition,
mTORC1 also induces lipogenesis in the liver through activat-
ing transcription factors SREBP1 and PPARγ, inhibits autophagy
through phosphorylation of the ULK1–Atg13–FIP200 complex,
andpromotesmitochondrialbiogenesisbyactivatingPGC1α/YY1
(Zoncu et al., 2011). mTORC2 exerts its effects on metabolism,
stressresponses,apoptosis,andcytoskeletonorganizationthrough
phosphorylation of many AGC kinases including Akt, serum-and
glucocorticoid-induced protein kinase (SGK), protein kinase C-α
(PKCα), and Rho1 GDP–GTP exchange protein-2 (Rom2; Sar-
bassovetal.,2005;FrostandLang,2011).SincemTORC2activates
Akt that in turn enhances mTORC1 activity through inactiva-
tion of TSC1–TSC2,mTORC2 is the upstream of mTORC1 upon
stimulation by growth factors (see Figure 1).
EVIDENCE FOR A ROLE OF mTORC1–S6K1 IN REGULATION OF
LONGEVITY
The role of mTORC1–S6K1 as a master determinant in longevity
control stems from experiments in almost all model organ-
isms including yeast, worms, ﬂies, and mice. Genetic inactiva-
tion of TOR or core components of TOR signaling including
S6K1orpharmacologicalinhibitionof thesignalingpathwaywith
rapamycin showed lifespan extension in yeast and invertebrates
and also recently in mice (Chen et al., 2009; Harrison et al., 2009;
Selmanetal.,2009).Theseindependentstudiesclearlyveriﬁedthe
important role of mTORC1–S6K1 in mammalian aging. No data
is available, yet, whether mTORC2 is also involved in regulation
of longevity. The lifespan extension experiments with rapamycin
may not fully exclude a possible role of mTORC2 in regulation of
longevity, since long-term rapamycin treatment is able to inhibit
mTORC2 in certain cell types (Sarbassov et al.,2006).
Furthermore, the effect of mTOR signaling inhibition on
longevity can be mimicked by caloric restriction, i.e., reduction
in calorie intake without malnutrition, across different species
(Pan et al., 2007; Evans et al., 2011; Shinmura et al., 2011). A
recent report demonstrating that caloric restriction also slows
aging in rhesus monkeys (Colman et al., 2009) may suggest that
caloric restriction could have anti-aging effects in humans (Kae-
berlein and Kennedy, 2009). Indeed, it has been reported that the
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Okinawan populations who consume 20% less calories compared
to the average caloric consumption of the Japanese population
live longer and display lower incidences of cancer and cardiovas-
cular diseases in the elderly. The healthier aging status disappears
in those who switched to Western diet (Kagawa, 1978; Willcox
et al., 2007). A small caloric restriction study in adult humans
over 6years demonstrates less cardiovascular risk factors includ-
ing lower body mass index, body fat deposition, blood pressure,
fasting plasma levels of glucose and insulin, lower inﬂammation
markers, i.e., tumor necrosis factor-α and C-reactive protein, and
beneﬁcial lipid proﬁles (Fontana et al.,2004) and shows better left
ventricular diastolic function than healthy age-and sex-matched
controls (Meyer et al., 2006). Also, caloric restriction improves
cardiac function in patients with type 2 diabetes (Hammer et al.,
2008). Whether the beneﬁcial effects of caloric restriction in
humans are due to healthier diet and could be translated to lifes-
pan extension in healthy elderly subjects and improve survival
in patients requires further investigation. The underlying mecha-
nisms of caloric restriction on longevity may involve reduction of
mTORC–S6K1 signaling. In yeast and ﬂies, when TOR is inacti-
vated, caloric restriction does not show further effects on lifespan
extension (Kapahi and Zid, 2004; Powers et al., 2006). Whether
this holds true also in humans needs to be conﬁrmed.
Another piece of supporting evidence for mTORC1–S6K1 in
regulation of longevity derives from experiments showing that
down-regulationof insulinandinsulin-likegrowthfactor(IGF-1)
signaling in mouse models such as haploinsufﬁciency of IGF-
1 receptor and global deletion of insulin receptor substrate-1
(IRS-1) are associated with reduced mTORC1–S6K1 signaling
and increased longevity in mice (Holzenberger et al., 2003; Sel-
man et al., 2008) as in yeast, nematodes, and fruit ﬂies (Stanfel
et al., 2009). Moreover, caloric restriction prolongs lifespan in
animal models, which is associated with reduced mTORC1–S6K1
mediated by IGF-1 signaling pathway (Estep et al., 2009; Fontana
etal.,2010).TheseresultsfurtherstrengthentheroleofmTORC1–
S6K1 in lifespan regulation in mammals. The exact mechanisms
of reduced signaling of mTORC1–S6K1 and IGF-1 under caloric
restriction,however,remainelusive.ItseemsthatAMPKandSirt1,
whose activities are augmented by caloric restriction,are involved
in negative regulation of mTORC1–S6K1 signaling and in turn
regulate aging process (Cohen et al., 2004; Canto et al., 2009;
Shackelford and Shaw, 2009; Figure 1), although direct evidence
for it in mammals is still lacking (Herranz and Serrano, 2010). It
is also noteworthy that loss of S6K1 in mice reciprocally results
in activation of AMPK which has been proposed to mediate the
lifespan extension (Selman et al., 2009). Intriguingly, persistent
activation of AMPK seems to play an important role in vascu-
lar endothelial cell senescence (Zu et al., 2010). A working model
of reciprocal regulatory effects of Sirt1 and AMPK on cellular
senescence and aging is discussed byWang et al. (2011). The mol-
ecularmechanismsof thereciprocalinterplaybetweenmTORC1–
S6K1 and AMPK and Sirt1 are not clear. A mutual inhibition of
mTORC1–S6K1 and AMPK has been reported (Lee et al., 2010).
Although the role of inhibition of mTORC1–S6K1 in lifespan
extension is consistently demonstrated in animal models, very
little information is available about the role of mTORC1–S6K1
in cardiovascular aging or age-associated cardiovascular diseases.
mTORC1–S6K1 SIGNALING IN CARDIOVASCULAR AGING
CARDIAC AGING
Age-associated cardiovascular diseases are accompanied by struc-
tural and functional changes in heart and blood vessels. These
aging-associated changes in cardiovascular system are referred to
as cardiovascular aging phenotypes. Cardiac aging is manifested
by maladaptation to stress, cardiac dysfunction, and heart fail-
ure. Cardiac aging process involves cardiomyocytes and other
cell types in the heart, such as interstitial ﬁbroblasts and vas-
cular cells. The morphological and functional changes of these
cells with aging lead to cardiac hypertrophy and dilation, car-
diac ﬁbrosis due to chronic deposition, and remodeling of extra-
cellular matrix produced mainly by ﬁbroblasts. Moreover, a
decreased regenerative capacity of cardiac stem cells,possibly due
to impaired cell division and accelerated cell senescence and an
increased cardiac myocyte death due to necrosis and apoptosis
with aging, may also contribute to cardiac dysfunction in elderly.
These pathological and clinical aspects of cardiac remodeling in
aging have been recently reviewed in great details (Shih et al.,
2011).
TherearecompellingevidencesdemonstratingthatmTORC1–
S6K1 signaling is involved in cardiac hypertrophy under vari-
ous pathological conditions including diabetes and hypertension
(Sadoshima and Izumo, 1995; Boluyt et al., 1997; Tu et al., 2002;
McMullenetal.,2004;Soesantoetal.,2009;KurdiandBooz,2011;
Sung et al., 2011). The underlying mechanisms have been pro-
posed to be attributed to both an increase in protein synthesis
uponstressstimulationandadecreaseinproteindegradationdue
to inhibition of autophagy by mTORC1 signaling (Hands et al.,
2009). However, evidence for this hypothesis needs to be demon-
strated. Inhibition of mTORC1–S6K1 pathway by rapamycin or
activation of AMPK by 5-aminoimidazole-4-carboxamide ribo-
side (AICAR) to negatively regulate mTORC1 signaling has been
shown to attenuate pressure overload-induced cardiac hypertro-
phy in vivo (Li et al., 2007). Conversely, deﬁciency in AMPK
enhances mTORC1–S6K1 signaling and exacerbates myocardial
hypertrophy in response to pressure overload (Zhang et al.,
2008).
Besides pressure overload, many hormonal factors, e.g.,
angiotensin-II, insulin, endothelin-1, catecholamine, etc., that are
elevated in plasma and/or tissues under various cardiovascular
pathologiesandinaging,havebeenshowntostimulatemTORC1–
S6K1 signaling in the cardiovascular system (Moschella et al.,
2007; Muniyappa et al., 2007; Kim et al., 2012). Activation of
mTORC1–S6K1 by the hormones,e.g.,angiotensin-II and also by
overnutrition (Glazer et al., 2009) participates in cardiac hyper-
trophy and vascular remodeling, and causes insulin resistance, an
important cardiovascular risk (Reaven, 2011), through phospho-
rylationof IRS-1atserineresidues(Kimetal.,2012).Importantly,
under the condition of cardiovascular insulin resistance, there is
a selective inhibition of the metabolic pathway, i.e., Akt–eNOS
in response to insulin,while the growth pathway,i.e.,p44/p42ERKs
remainsactive(Muniyappaetal.,2007).Thisselectiveinsulinresis-
tance may play an important role in decreased vascular relaxation
due to impaired eNOS activation and enhanced cardiovascu-
lar remodeling in metabolic disorders such as type II diabetes
(Muniyappa et al., 2007). mTORC1–S6K1 pathway is therefore
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considered as an important molecular link between metabolic
stress and cardiovascular abnormalities.
Despite the evidences for a role of mTORC1–S6K1 signaling
in agonist or pressure-induced cardiac hypertrophy, only little
information is available about the signaling of mTORC1–S6K1
in physiological process of aging heart. An early study using
microarray analyses reported that gene expression pattern asso-
ciated with mTOR is suppressed in aging heart of Fischer 344 rats
(Linford et al., 2007), while a recent study shows no difference
in mTORC1–S6K1 activity (measured by phosphorylated mTOR
and S6K1 levels) in the heart between 8 and 30month old rats
of the same strain (Shinmura et al., 2011). There are two points
that should be considered for interpretation of the inconsistent
results. First, microarray has its limitation in elucidating signal-
ing pathways, because signaling molecules are mainly enzymes
whose activities could not be investigated with this experimen-
talapproach;second,aging-associatedkineticsof mTORC1–S6K1
signalingmayexist,meaninganenhancedsignalingwithtimefol-
lowed by a decreased signaling in old age. Indeed, a decreased
mTOR signaling has been shown to play a role in sarcopenia in
advanced age (Sakuma and Yamaguchi, 2010). Whether this also
occurs in the heart requires investigation. Nevertheless, caloric
restrictionintheoldratsshowedimproveddiastolicfunctionasso-
ciated with reduced cell senescence and mTORC1–S6K1 signaling
in the heart compared to the old animals fed ad libitum (Shin-
mura et al., 2011), suggesting that mTORC1–S6K1 is involved
in caloric restriction-induced improvement of heart function in
aging. It is also conceivable that the anti-cellular senescence effect
and reduced mTORC1–S6K1 signaling contribute to the beneﬁ-
cial effects of caloric restriction on human heart function (Meyer
et al.,2006; Hammer et al., 2008).
VASCULAR AGING
Endothelial dysfunction and inﬂammatory activation
In the vasculature, increased arterial wall thickening and gen-
eralized vascular stiffness occur with aging. This vascular aging
phenotype is attributed to vascular calciﬁcation, increased colla-
gencontentandelastinbreakdown,andelevatedlevelsofadvanced
glycation end products. Vascular inﬂammation, oxidative stress,
endothelial dysfunction, endothelial progenitor cell dysfunction,
vascular cell apoptosis all intertwine with each other to affect vas-
cularagingprocess,whichacceleratescoronaryheartdisease,heart
failure, stroke, and dementia (Ungvari et al.,2010).
In the past decades, much attention has been devoted to
endothelial dysfunction in aging. Evidence demonstrates that
besides the enhanced production of endothelium-derived vaso-
constrictor prostanoids, which is due to augmented expression
and/or activity of cyclo-oxygenases in endothelial cells during
aging (Vanhoutte et al., 2009), decreased endothelial nitric oxide
(NO) bioavailability is a major characteristic of vascular aging,
whichisindependentof othercardiovascularriskfactors(Lakatta,
2001). Endothelial NO causes vascular relaxation,inhibits platelet
aggregation,andleukocyteadhesion(YangandMing,2006).Clin-
ical studies provide evidence that endothelial dysfunction is not
only highly associated with cardiovascular disease, it also predicts
future cardiac events (Schachinger et al.,2000; Halcox et al.,2002;
Bugiardini et al., 2004; Huang et al., 2007). eNOS dysfunction
seems causally involved in cardiovascular aging, since eNOS−/−
male mice have a signiﬁcantly shorter lifespan than their wild
type controls and exhibit accelerated cardiac dysfunction with age
(Wei,2004).EndothelialcellswithdysfunctionaleNOSinagingare
also more vulnerable to apoptotic stimuli (Hoffmann et al., 2001;
Csiszar et al., 2004). There is increasing evidence suggesting that
the number and regenerative capacity of circulating endothelial
progenitorcellswhichplayaroleinreendothelializationandrepair
after vascular injury are decreased in patients with cardiovascular
diseasesandriskfactorsincludingaging(Vasaetal.,2001;Hilletal.,
2003; Rauscher et al., 2003; Werner et al., 2005). The underlying
mechanisms of eNOS dysfunction in aging are multifactorial and
havenotbeenfullyunderstood,yet.DecreasedeNOSgeneexpres-
sion (Csiszar et al., 2002; Tanabe et al., 2003) or increased eNOS
gene expression with impaired enzymatic activity due to oxidative
stressareimportantmechanisms(Stockklauser-Farberetal.,2000;
vanderLooetal.,2000;Mingetal.,2004;Desroisetal.,2010).The
up-regulation of eNOS gene in aging and also in other vascular
disease may represent a compensatory mechanism counteract-
ing oxidative stress (Drummond et al., 2000; Stockklauser-Farber
et al.,2000; Hink et al.,2001).
Oxidative stress has been proposed as the culminant mecha-
nism impairing endothelial function via quenching of NO, i.e.,
inactivation of NO by increased production of O−
2 , which leads to
formationof peroxynitrite,astrongoxidantthatcanfurtherdam-
age endothelial cells in aging (van der Loo et al., 2000; Brandes
et al., 2005). Among other sources, eNOS itself produces signiﬁ-
cant amount of O−
2 in endothelial cells,when“eNOS uncoupling”
occurs – that is, eNOS generates O−
2 instead of NO (Landmesser
etal.,2003;ForstermannandMunzel,2006;Rajapakseetal.,2011).
It seems that normal function of eNOS requires homodimeriza-
tion of the enzyme which is stabilized by the cofactor BH4.T h e
eNOS reductase domain generates electron ﬂow from NADPH
through FAD and FMN ﬂavins, which are then transferred to the
oxidasedomainof othermonomersinwhich l-arginineismetab-
olizedtoNOatthehemegroupintheactivesite(Forstermannand
Munzel,2006).IntheabsenceofBH4 duetooxidativeinactivation,
eNOSdimer/monomerratioisdecreasedandthecatalyticactivity
becomes uncoupled – that is – uncoupling of NADPH oxidation
and NO synthesis, with oxygen instead of l-arginine as termi-
nal electron acceptor, resulting in O−
2 generation (Forstermann
and Munzel, 2006). In addition, limited speciﬁc pool of intracel-
lular l-arginine bioavailability due to enhanced arginase activity
(Csiszar et al., 2002; Berkowitz et al., 2003; Tanabe et al., 2003)o r
production of endogenous eNOS inhibitor asymmetric dimethy-
larginine (ADMA; Sydow and Munzel, 2003; Antoniades et al.,
2009) have been also reported to contribute to endothelial dys-
function in aging. The ﬁnding that eNOS enzymatic dysfunction
isthemajormechanismforendothelialdysfunctioninagingindi-
cates that one should therapeutically focus on improving eNOS
enzymatic function instead of increasing eNOS gene expression
in blood vessels. Indeed, over-expression of eNOS under disease
conditions for example in atherosclerosis prone ApoE−/− mice
has been shown to accelerate atherosclerosis (Ozaki et al., 2002).
EndothelialspeciﬁceNOStransgenicmicehaveenhancedO−
2 gen-
eration which can be inhibited by the eNOS inhibitor L-NAME or
by endothelial-targeted GTP cyclohydrolase 1 over-expression to
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increase BH4 production (Bendall et al., 2005). The results fur-
therimplicatethattoomucheNOSunderpathologicalconditions
where the enzyme is uncoupled, is detrimental. A recent study
reveals that oxidative stress causes cysteine S-glutathionylation
of the reductase domain of eNOS, resulting eNOS uncoupling
(Chenetal.,2010).TheeNOSS-glutathionylationlevelisincreased
in spontaneously hypertensive rats as compared to normoten-
siveanimalsaccompaniedwithimpairedendothelium-dependent
relaxations that can be reversed after the S-glutathionylation of
eNOS is removed by thiol-speciﬁc reducing agents (Chen et al.,
2010). Whether S-glutathionylation of eNOS also plays a role in
endothelial dysfunction in aging requires further investigation.
Another important feature of endothelial aging is enhanced
expression of inﬂammatory adhesion molecules such as ICAM-1
and VCAM-1 (Gorgoulis et al., 2003; Zhou et al., 2006; Ung-
vari et al., 2010), which leads to enhanced monocyte–endothelial
interaction and accelerated atherogenesis. There are considerable
evidences suggesting that oxidative stress is a major mechanism
for promoting eNOS dysfunction as well as vascular inﬂamma-
tion which causes further endothelial dysfunction and aging in
a positive-feedback manner (Herrera et al., 2010). However, evi-
dence for a causal role of oxidative stress in vascular aging is still
lacking,althoughthereisnodoubtthatoxidativestresscontributes
to aging-associated vascular dysfunctions. Some authors suggest
that mTOR signaling instead of oxidative stress might be the
more powerful driving force for organismal aging (Blagosklonny,
2008).
Causal role of mTORC1–S6K1 signaling in endothelial aging
Although evidence for a role of mTOR–S6K1 signaling in regu-
lation of organism lifespan has been well demonstrated (Evans
et al.,2011;Zoncu et al.,2011),it is,however,not known,whether
mTORC1–S6K1 signaling pathway participates in vascular aging.
In contrast to the aging heart, an increased basal activity of
mTORC1–S6K1 has been demonstrated in aortas of old Fischer
344xBrownNorwayF1hybridrats(Riceetal.,2005),whichimpli-
cates a potential role of mTORC1–S6K1 signaling in vascular
aging. However, a study reported that inhibition of mTORC1–
S6K1 by rapamycin and everolimus induces endothelial cellular
senescenceinculture(Otaetal.,2009),whichdoesnotsupportthe
role of mTORC1–S6K1 in endothelial aging. One has to take into
accountthattheformerstudyshowscorrelationbetweenincreased
mTORC1–S6K1signalingandvascularaging,whilethelatterused
pharmacological inhibitors in young endothelial cells. The drugs
may exert some non-speciﬁc effects which could interfere with
the interpretation. Moreover, the function of mTORC1–S6K1 in
young and old cells or organisms might be different. A regulated
function of mTORC1–S6K1 signaling is necessary for organism
development, while a persistent non-regulated mTORC1–S6K1
signaling is detrimental.
By pharmacological and genetic approaches, we demonstrate
a hyperactive S6K1 activity in two aging model systems, i.e.,
in cultured senescent endothelial cells and in aortas of natu-
rally aging rats as compared to young cells and young animals
(Rajapakseetal.,2011).Apersistentactivationof mTORC1–S6K1
signaling is also shown to be associated with hematopoietic stem
cells in old mice, which is responsible for decreased regenerative
capacity of the stem cells in aging (Chen et al., 2009). Inhibition
of mTORC1–S6K1 pathway either with rapamycin or with S6K1
silencing improves NO production and inhibits O−
2 production
in senescent cells and old rat aortas. The enhanced O−
2 produc-
tion in senescent cells and old rat aortas can be eliminated by
the eNOS inhibitor L-NAME, demonstrating eNOS uncoupling
in aging (Rajapakse et al., 2011). Conversely, over-expression of a
S6K1activemutantinyoungendothelialcellscauseseNOSuncou-
plingandendothelialsenescence,whichprovidestheﬁrstevidence
for a causative role of S6K1 in eNOS uncoupling and endothe-
lial aging. How S6K1 drives endothelial senescence or aging and
causes eNOS uncoupling, and whether S6K1 causes endothelial
aging through eNOS uncoupling remain to be investigated.
Endothelial aging is also associated with increased expression
of the coagulation factor tissue factor (TF) as well as adhesion
molecules ICAM-1 andVCAM-1 (Csiszar et al.,2008),which may
promote thrombosis and vascular inﬂammation in elderly sub-
jects. Numerous studies including our own report the inhibitory
effect of mTORC1 on TF expression based on the observation
that rapamycin or silencing mTOR enhances TF expression in
endothelial cells (Camici et al., 2010; Ming et al., 2010). How-
ever, silencing S6K1 reduces TF protein level in endothelial cells
stimulated with thrombin or TNFα without affecting TF mRNA
expression. Conversely, over-expression of a constitutively active
S6K1mutantenhancesTFproteinleveleveninthemTOR-silenced
cells(Mingetal.,2010).Theresultsrevealanunexpectedopposing
effect of mTOR and S6K1 on endothelial TF expression and are
best explained by the mechanisms that the markedly enhanced TF
mRNA expression under the condition of mTORC1 inhibition is
translated by S6K1-independent pathways such as RhoA, NF-κB,
and p38mapk (Ming et al., 2010), since blockade of RhoA, NF-
κB, and p38mapk either pharmacologically or genetically is able
to reduce the up-regulation of TF protein level (Figure 2). The
uncoupling effect of mTOR and S6K1 has also been reported in
skeletal muscle cells (Cunningham et al., 2007a). These ﬁndings
may have potential clinical implications. TF is highly expressed in
cells within atherosclerotic plaques (Hatakeyama et al., 1997). It
has been reported that vascular injury after coronary intervention
increases circulating TF activity in patients (Tutar et al., 2003),
which favors thrombus formation after coronary intervention.
With rapamycin (sirolimus)-eluting stents, TF expression in the
vasculature and release from vascular cells including endothelial
cells,smoothmusclecells,andmacrophagesmightbeexaggerated
because of the stimulating effect of TF expression by the drug.
This effect of rapamycin,may increase thrombotic risk,despite its
property of preventing vascular restenosis in patients with coro-
nary artery disease (Luscher et al., 2007), although inhibition of
endothelial regeneration and in turn endothelialization of stent
surface by drug-eluting stents may play a more prominent role
in stent thrombosis (Inoue et al., 2011). It would be interesting
to test whether inhibition of S6K1 alone, rather than mTORC1
as achieved by rapamycin, proves sufﬁcient to prevent vascular
restenosis and be superior in reducing thrombotic propensity
by developing speciﬁc S6K1 inhibitors. The same consideration
may be applied for anti-aging therapy. Moreover, silencing S6K1
in endothelial cells is able to prevent up-regulation of E-selectin
inducedbyTNFα(Mingetal.,2009),implicatingapossibleroleof
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FIGURE2|m T O R C 1 –S6K1 signaling in cardiovascular aging. Aging
accelerating factors cause persistent activation of the
Akt–mTORC1–S6K1 signaling.The hyperactive S6K1 has pleiotropic
effects in cardiovascular system. In heart, it causes cardiomyocytes
hypertrophy leading to cardiac maladaptation. In endothelium, it induces
eNOS uncoupling, endothelial senescence, and adhesion molecule
expression as well asTF protein expression. All of these effects
contribute to age-associated cardiovascular diseases such as heart
failure, atherosclerotic vascular disease.Thus inhibiting S6K1 with
resveratrol or mTORC1 inhibitor rapamycin may have beneﬁcial effect in
treatment of age-associated cardiovascular diseases in clinic. It is
important to recognize that there are some uncoupled biological
function(s) of mTORC1 and S6K1 as reported for their opposing effect in
regulation ofTF expression. While mTOR suppresses endothelialTF
mRNA expression, S6K1 is required forTF protein translation, which
works in concert with other signaling pathways such as RhoA, p38mapk,
and NF-κB. Given this ﬁnding, drugs more speciﬁcally inhibiting S6K1
rather than mTORC1 should be developed and the effects of targeting
mTORC1 or S6K1 on aging-related cardiovascular diseases and
cardiovascular aging and beyond should be investigated.
S6K1 in regulation of endothelial–leukocyte interaction.Whether
S6K1 is involved in TF as well as adhesion molecule expression in
aged endothelial cells and blood vessels warrants further investi-
gation.Theeffectsof mTORC1–S6K1oncardiovascularfunctions
are illustrated in Figure 2.
Resveratrol inhibits mTORC1–S6K1 and prevents endothelial aging
It is well demonstrated that resveratrol, a naturally occurring
polyphenol, slows aging process and exerts protective effects on
aging-associated pathologies including vascular diseases, type II
diabetes in animal models (Baur et al., 2006; Lagouge et al.,
2006; Barger et al., 2008; Pearson et al., 2008; Miller et al., 2011).
Numerous studies including ours demonstrate that resveratrol
inhibits ICAM-1 and VCAM-1 expression in endothelial cells in
response to high glucose and TNFα (Csiszar et al., 2006; Park
et al., 2009; Rajapakse et al., 2009). Interestingly, resveratrol is
capable of recoupling eNOS, leading to inhibition of superoxide
generationandincreaseinendothelialNOproductioninsenescent
endothelial cells and in aged rat aortas partly through inhibition
of mTORC1–S6K1 signaling (Rajapakse et al., 2011), since NO
production stimulated by acetylcholine is only partly restored by
resveratrol and rapamycin in old rats. Additional defects in eNOS
dysfunction as discussed must be present.
It also remains to be investigated whether resvera-
trol’s inhibitory effect on mTORC1–S6K1–eNOS-uncoupling is
mediated through activation of the NAD+-dependent deacety-
lase Sirt1 (Lagouge et al., 2006; Zang et al., 2006; Baur, 2010),
whose activation has been shown to exhibit protection against
age-associated diseases including diabetes and atherosclerosis
(Lagouge et al., 2006; Zang et al., 2006; Pearson et al., 2008),
although current studies do not show life extending effect in
mammals (Lagouge et al., 2006; Barger et al., 2008; Pearson et al.,
2008;Milleretal.,2011).Recentstudiesprovideevidenceshowing
that resveratrol also exerts pleiotrophic effects independently of
Sirt1 (Zhang, 2006; Pirola and Frojdo, 2008; Kitada et al., 2011).
It has also been shown that resveratrol may indirectly activate
Sirt1 through AMPK, which has been demonstrated to inhibit
mTORC1–S6K1 pathway in different cell types (Ruderman et al.,
2010). The underlying mechanisms by which resveratrol inhibits
mTORC1–S6K1 in aging endothelial cells are not clear, yet. Since
the hyperactive Akt, an upstream signaling of mTORC1–S6K1
pathway, is observed in senescent endothelial cells and is inhib-
itedbyresveratrol(Rajapakseetal.,2011),itseemsthatresveratrol
negatively regulates mTORC1–S6K1 pathway through inhibition
ofmTORC2.ThepersistentactivationofAkt–mTORC1–S6K1sig-
nalinginendothelialagingobservedinourstudyisconsistentwith
the ﬁnding that a hyperactive Akt plays a role in endothelial cell
senescence (Miyauchi et al., 2004). Further studies need to estab-
lisharoleof mTORC2inendothelialsenescenceandinregulation
of longevity.
Frontiers in Physiology | Vascular Physiology January 2012 | Volume 3 | Article 5 | 6Ming et al. S6K1 in cardiovascular aging
RAPAMYCIN AND RESVERATROL AS ANTI-AGING AND
ANTI-CARDIOVASCULAR AGING DRUGS IN HUMANS?
Although caloric restriction seems the most promising approach
to slow aging and onset of age-related diseases in humans with
almost no recognizable adverse effects (Fontana et al., 2010), it is
difﬁcult to implement as a routine and long-term preventive or
treatment modality in humans. The primary target of anti-aging
strategy should focus on treatment of age-related diseases and not
longevity,i.e.,improvement of“healthy”lifespan. By treatment of
age-related diseases,healthy lifespan extension,and improvement
of life quality in elderly are expected.
Inanimalmodels,rapamycinisabletoextendlifespanandpre-
ventsmanyage-relateddiseasessuchascancer(Hudesetal.,2007),
obesity (Um et al.,2004),cardiovascular diseases (Sadoshima and
Izumo, 1995; Elloso et al., 2003; Waksman et al., 2003; McMullen
etal.,2004;Pakalaetal.,2005;Adelman,2010). Moreover,a recent
studyreportsthatinculturedﬁbroblastsisolatedfrompatientssuf-
fering Hutchinson–Gilford Progeria Syndrome (HGPS), a lethal
geneticdiseasecharacterizedbyprematureaginganddeathinado-
lescence or the teen years,rapamycin postpones cell senescence by
activating autophagy, a process by which cells clear junk protein
and trashed organelles and is inhibited by hyperactive mTORC1–
S6K1 (Cao et al., 2011). These ﬁndings suggest an additional
mechanism for the beneﬁcial effects of rapamycin on aging.
Interestingly, many of the beneﬁcial effects of rapamycin have
been shared with resveratrol (Jang et al., 1997; Baur et al.,
2006; Zang et al., 2006; Chan et al., 2008; Smoliga et al., 2011),
although the lifespan extending effect could be demonstrated
with rapamycin but not with resveratrol in mice (Pearson et al.,
2008; Harrison et al., 2009; Miller et al., 2011). Both rapamycin
and resveratrol inhibit hyperactive mTORC1–S6K1 signaling,
improveendothelialfunctioninsenescentcellsandagingrataortas
(Rajapakse et al., 2011), and also improve bone marrow-derived
progenitor cell function and senescence (Chen et al.,2009; Huang
et al.,2010). All the results suggest that rapamycin and resveratrol
may be used as anti-aging therapeutics in humans. Rapamycin
and analogs are indeed used in patients with organ transplanta-
tion and cancer and show clinical beneﬁts (Kauffman et al., 2005;
Law,2005; Stallone et al.,2005; Zmonarski et al.,2005; Campistol
et al., 2006). However, there is concern about some undesirable
effects of rapamycin which may limit its systemic use as anti-
aging or anti-cardiovascular aging drug. In contrast to the initial
major concern about immunosuppressive effects, rapamycin has
beenshowntoimproveimmunefunctionandregenerativecapac-
ity of bone marrow stem cells in old mice (Chen et al., 2009).
However, early studies in animal models treated with rapamycin
reported multiple adverse effects including deregulated glucose
homeostasis, hyperlipidemia (Cunningham et al., 2007b; Chang
et al., 2009). In humans, rapamycin increases blood triglyceride
and cholesterol resulting from lipolysis (Morrisett et al., 2002;
Ribes et al., 2005),which may have negative impact on cardiovas-
cular functions and metabolic homeostasis, although rapamycin
has been shown to reduce atherosclerosis in mouse models (Basso
et al., 2003; Elloso et al., 2003; Waksman et al., 2003; Pakala et al.,
2005). The different effects of rapamycin in mice may be related
to when the rapamycin therapy is initiated (early or late in life)
or how long the therapy persists, or whether chronic persistent
or pulsed therapy is instrumented. Finally, it may depend on
whether young or old, healthy or diseased animals are treated
with the drug. It is important to point out that rapamycin may
be beneﬁcial under the condition when mTORC1–S6K1 signal-
ing is inappropriately consistently elevated, for example in aging,
but detrimental if its activity under physiological conditions is
abolished.Furthermore,takingintoaccountthatanopposingand
uncoupling effect of mTORC1 and S6K1 has been demonstrated
such as in regulation of endothelial TF expression (Ming et al.,
2010), and that both rapamycin and resveratrol inhibit mTORC1
at the level and upstream of mTORC1, respectively (Figure 2), it
would be worth to test whether targeting S6K1 directly would
be a better approach than targeting mTORC1 as achieved by
rapamycin or resveratrol. For this purpose, speciﬁc inhibitor of
S6K1 should be developed. At the molecular level,since off-target
effects of the drugs could not be excluded, more speciﬁc experi-
mentalapproachessuchasmutants(activeordominantnegative),
RNA interference,or targeted gene disruption of mTORC1–S6K1
signalingshouldbeappliedtoevaluatetheirrolesincardiovascular
systems.
So far, almost no undesirable effects of resveratrol have been
reported, which might be due to the fact that this drug is newly
investigated as compared to rapamycin. The ﬁrst recently pub-
lished human study with resveratrol conﬁrmed metabolic beneﬁ-
cial effects which were previously observed in animals (Timmers
et al., 2011). The study showed that treatment of healthy, obese
men with 150mg/day resveratrol for 30days mimicked the effects
of calorie restriction,signiﬁcantly improved metabolic proﬁles on
circulatingglucose,triglycerides,liverlipidcontent,anddecreased
inﬂammationmarkersandsystolicbloodpressure(Timmersetal.,
2011). The effects of resveratrol on cardiovascular diseases in
patients remain to be demonstrated. Further, dosage dependent
side effects of resveratrol should be investigated,especially for the
newly developed derivatives which show much stronger effects
than resveratrol on Sirt1 activity (Milne et al.,2007). The potency
of a drug is usually associated with toxicity due to non-speciﬁc
off-target effects.
CONCLUSION AND PERSPECTIVES
Emerging evidence demonstrates that targeting mTORC1–S6K1
signaling could be a promising therapeutic modality to slow aging
process and treat cardiovascular disease in aging. Future work
should further elucidate the mechanisms of persistent hyperac-
tive mTORC–S6K1 and the mechanisms of cardiovascular aging
driven by mTORC1–S6K1. Since mTORC1–S6K1 signaling is
also essential for normal development and skeletal muscle mass
growth, undesirable side effects of targeting mTOCR1–S6K1
may be avoided by short treatment instead long-term treat-
ment. In addition, drugs more speciﬁcally inhibiting S6K1 rather
than mTORC1 should be developed and the effects of targeting
mTORC1 or S6K1 on aging-related cardiovascular diseases and
cardiovascular aging and beyond should be investigated.
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